Physiological, Pathophysiological and Therapeutic Roles of Heparin and Heparan Sulfate

Carbohydrate Chemistry, Biology and Medical Applications

Volumn , Issue , 2008, Pages 227-251

  Xie, Jin ^a   Murugesan, Saravanababu ^a   Linhardt, Robert J ^a,b  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^b Research Rensselaer Polytechnic Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956416918     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-08-054816-6.00010-0     Document Type: Chapter

References (107)

1. R Sasisekharan and G Venkataraman (2000) Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol 4 626-631.
2. DJ Tyrrell, S Kilfeather and CP Page (1995) Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 16 198-204.
3. I Capila and RJ Linhardt (2002) Heparin–protein interactions. Angew Chem Int Ed 41 390-412.
4. LB Jacques (1979) Heparin: an old drug with a new paradigm. Science 206 528-533.
5. RJ Linhardt (2003) Perspective: 2003 Claude S. Hudson award address in carbohydrate chemistry. Heparin: structure and activity. J Med Chem 46 2551-2554.
6. R Sasisekharan, Z Shriver, G Venkataraman and U Narayanasami (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2 521-528.
7. RE Hileman, RN Jennings and RJ Linhardt (1998) Thermodynamic analysis of the heparin interaction with a basic cyclic peptide using isothermal titration calorimetry. Biochemistry 37 15231-15237.
8. J Bae, UR Desai, A Pervin, EE Caldwell, JM Weiler and RJ Linhardt (1994) Interaction of heparin with synthetic antithrombin III peptide analogues. Biochem J 301(Pt. 1), 121-129.
9. ST Olson and YJ Chuang (2002) Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc Med 12 331-338.
10. ST Olson, I Bjork, R Sheffer, PA Craig, JD Shore and J Choay (1992) Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 267 12528-12538.
11. L Jin, JP Abrahams, R Skinner, M Petitou, RN Pike and RW Carrell (1997) The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 94 14683-14688.
12. DJ Johnson, W Li, TE Adams and JA Huntington (2006) Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. Embo J 25 2029-2037.
13. UR Desai, M Petitou, I Bjork and ST Olson (1998) Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin. J Biol Chem 273 7478-7487.
14. M Rusnati, E Tanghetti, P Dell'Era, A Gualandris and M Presta (1997) αvβ3 Integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. Mol Biol Cell 8 2449-2461.
15. DE Johnson, LT Williams, A Gritli-Linde, P Lewis, AP McMahon and A Linde (1993) Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60 1-41.
16. L Pellegrini, DF Burke, F. Delft Fv, B Mulloy and TL Blundell (2000) Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407 1029-1034.
17. CJ Robinson, NJ Harmer, SJ Goodger, TL Blundell and JT Gallagher (2005) Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1-FGFR2c-Heparin ternary complexes. J Biol Chem 280 42274-42282.
18. J Schlessinger, AN Plotnikov, OA Ibrahimi, AV Eliseenkova, BK Yeh, A Yayon, RJ Linhardt and M Mohammadi (2000) Crystal structure of a ternary FGF-FGFR-Heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 6 743-750.
19. OA Ibrahimi, F Zhang, SC Hrstka, M Mohammadi and RJ Linhardt (2004) Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. Biochemistry 43 4724-4730.
20. LE Kemp, B Mulloy and E Gherardi (2006) Signalling by HGF/SF and Met: the role of heparan sulphate co-receptors. Biochem Soc Trans 34 414-417.
21. M Lyon, JA Deakin and JT Gallagher (2002) The mode of action of heparan and dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor. J Biol Chem 277 1040-1046.
22. D Lietha, DY Chirgadze, B Mulloy, TL Blundell and E Gherardi (2001) Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. Embo J 20 5543-5555.
23. CW Vander Kooi, MA Jusino, B Perman, DB Neau, HD Bellamy and DJ Leahy (2007) Structural basis for ligand and heparin binding to neuropilin B domains. Proc Natl Acad Sci USA 104(15), 6152-6157.
24. CR Parish (2006) The role of heparan sulfate in inflammation. Nat Rev Immunol 6 633-643.
25. K Shikata, Y Suzuki, J Wada, K Hirata, M Matsuda, H Kawashima, T Suzuki, M Iizuka, H Makino and M Miyasaka (1999) L-selectin and its ligands mediate infiltration of mononuclear cells into kidney interstitium after ureteric obstruction. J Pathol 188 93-99.
26. H Kawashima, N Watanabe, M Hirose, X Sun, K Atarashi, T Kimura, K Shikata, M Matsuda, D Ogawa, R Heljasvaara, M Rehn, T Pihlajaniemi and M Miyasaka (2003) Collagen XVIII, a basement membrane heparan sulfate proteoglycan, interacts with L-selectin and monocyte chemoattractant protein-1. J Biol Chem 278 13069-13076.
27. JWAM Celie, ED Keuning, RHJ Beelen, AM Drager, S Zweegman, FL Kessler, R Soininen and JVD Born (2005) Identification of L-selectin binding heparan sulfates attached to collagen type XVIII. J Biol Chem 280 26965-26973.
28. RP McEver, KL Moore and RD Cummings (1995) Leukocyte trafficking mediated by selectin-carbohydrate interactions. J Biol Chem 270 11025-11028.
29. Y-Q Ma and J-G Geng (2000) Heparan sulfate-like proteoglycans mediate adhesion of human malignant melanoma A375 cells to P-selectin under flow. J Immunol 165 558-565.
30. TA Springer (1994) Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76 301-314.
31. J Middleton, S Neil, J Wintle, I Clark-Lewis, H Moore, C Lam, M Auer, E Hub and A Rot (1997) Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91 385-395.
32. L Wang, M Fuster, P Sriramarao and JD Esko (2005) Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 6 902-910.
33. Z Johnson, MH Kosco-Vilbois, S Herren, R Cirillo, V Muzio, P Zaratin, M Carbonatto, M Mack, A Smailbegovic, M Rose, R Lever, C Page, TN Wells and AE Proudfoot (2004) Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J Immunol 173 5776-5785.
34. E Oberlin, A Amara, F Bachelerie, C Bessia, JL Virelizier, F Arenzana-Seisdedos, O Schwartz, JM Heard, I Clark-Lewis, DF Legler, M Loetscher, M Baggiolini and B Moser (1996) The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382 833-835.
35. E Mbemba, JC Gluckman and L Gattegno (2000) Glycan and glycosaminoglycan binding properties of stromal cell-derived factor (SDF)-1alpha. Glycobiology 10 21-29.
36. R Sadir, F Baleux, A Grosdidier, A Imberty and H Lortat-Jacob (2001) Characterization of the stromal cell-derived factor-1alpha-heparin complex. J Biol Chem 276 8288-8296.
37. R Shamri, V Grabovsky, JM Gauguet, S Feigelson, E Manevich, W Kolanus, MK Robinson, DE Staunton, UH von Andrian and R Alon (2005) Lymphocyte arrest requires instantaneous induction of an extended LFA-1 conformation mediated by endothelium-bound chemokines. Nat Immunol 6 497-506.
38. MM Mota, G Pradel, JP Vanderberg, JC Hafalla, U Frevert, RS Nussenzweig, V Nussenzweig and A Rodriguez (2001) Migration of Plasmodium sporozoites through cells before infection. Science 291 141-144.
39. JB Dame, JL Williams, TF McCutchan, JL Weber, RA Wirtz, WT Hockmeyer, WL Maloy, JD Haynes, I Schneider, D Roberts, GS Sanders, EP Reddy, CL Diggs and LH Miller (1984) Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science 225 593-599.
40. C Cerami, U Frevert, P Sinnis, B Takacs, P Clavijo, MJ Santos and V Nussenzweig (1992) The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell 70 1021-1033.
41. U Frevert, P Sinnis, C Cerami, W Shreffler, B Takacs and V Nussenzweig (1993) Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J Exp Med 177 1287-1298.
42. D Rathore, TF McCutchan, DN Garboczi, T Toida, MJ Hernaiz, LA LeBrun, SC Lang and RJ Linhardt (2001) Direct measurement of the interactions of glycosaminoglycans and a heparin decasaccharide with the malaria circumsporozoite protein. Biochemistry 40 11518-11524.
43. BD Lindenbach and CM Rice (2005) Unravelling hepatitis C virus replication from genome to function. Nature 436 933-938.
44. D Rosa, S Campagnoli, C Moretto, E Guenzi, L Cousens, M Chin, C Dong, AJ Weiner, JY Lau, QL Choo, D Chien, P Pileri, M Houghton and S Abrignani (1996) A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 93 1759-1763.
45. M Flint and JA McKeating (2000) The role of the hepatitis C virus glycoproteins in infection. Rev Med Virol 10 101-117.
46. BD Lindenbach and CM Rice (2001) Flaviviridae: the viruses and their replication Baltimore: Lippincott Williams & Wilkins
47. F Penin, C Combet, G Germanidis, PO Frainais, G Deleage and JM Pawlotsky (2001) Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75 5703-5710.
48. H Barth, C Schafer, MI Adah, F Zhang, RJ Linhardt, H Toyoda, A Kinoshita-Toyoda, T Toida, TH Van Kuppevelt, E Depla, F Von Weizsacker, HE Blum and TF Baumert (2003) Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278 41003-41012.
49. H Barth, EK Schnober, F Zhang, RJ Linhardt, E Depla, B Boson, FL Cosset, AH Patel, HE Blum and TF Baumert (2006) Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol 80 10579-10590.
50. CC Rider, DR Coombe, HA Harrop, EF Hounsell, C Bauer, J Feeney, B Mulloy, N Mahmood, A Hay and CR Parish (1994) Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. Biochemistry 33 6974-6980.
51. RR Vives, A Imberty, QJ Sattentau and H Lortat-Jacob (2005) Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J Biol Chem 280 21353-21357.
52. D WuDunn and PG Spear (1989) Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J Virol 63 52-58.
53. BC Herold, SI Gerber, T Polonsky, BJ Belval, PN Shaklee and K Holme (1995) Identification of structural features of heparin required for inhibition of herpes simplex virus type 1 binding. Virology 206 1108-1116.
54. PG Spear, MT Shieh, BC Herold, D WuDunn and TI Koshy (1992) Heparan sulfate glycosaminoglycans as primary cell surface receptors for herpes simplex virus. Adv Exp Med Biol 313 341-353.
55. ME Lukashev and Z Werb (1998) ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol 8 437-441.
56. S Ricard-Blum, M Beraud, N Raynal, RW Farndale and F Ruggiero (2006) Structural requirements for heparin/heparan sulfate binding to type V collagen. J Biol Chem 281 25195-25204.
57. F Delacoux, A Fichard, C Geourjon, R Garrone and F Ruggiero (1998) Molecular features of the collagen V heparin binding site. J Biol Chem 273 15069-15076.
58. F Delacoux, A Fichard, S Cogne, R Garrone and F Ruggiero (2000) Unraveling the amino acid sequence crucial for heparin binding to collagen V. J Biol Chem 275 29377-29382.
59. R Gallo, C Kim, R Kokenyesi, NS Adzick and M Bernfield (1996) Syndecans-1 and -4 are induced during wound repair of neonatal but not fetal skin. J Invest Dermatol 107 676-683.
60. A Woods, RL Longley, S Tumova and JR Couchman (2000) Syndecan-4 binding to the high affinity heparin-binding domain of fibronectin drives focal adhesion formation in fibroblasts. Arch Biochem Biophys 374 66-72.
61. M Salmivirta, K Elenius, S Vainio, U Hofer, R Chiquet-Ehrismann, I Thesleff and M Jalkanen (1991) Syndecan from embryonic tooth mesenchyme binds tenascin. J Biol Chem 266 7733-7739.
62. KS Midwood, LV Williams and JE Schwarzbauer (2004) Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol 36 1031-1037.
63. MB Wenk, KS Midwood and JE Schwarzbauer (2000) Tenascin-C suppresses Rho activation. J Cell Biol 150 913-920.
64. KS Midwood, LV Valenick, HC Hsia and JE Schwarzbauer (2004) Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4. Mol Biol Cell 15 5670-5677.
65. BJ Dickson (2002) Molecular mechanisms of axon guidance. Science 298 1959-1964.
66. D Van Vactor, DP Wall and KG Johnson (2006) Heparan sulfate proteoglycans and the emergence of neuronal connectivity. Curr Opin Neurobiol 16 40-51.
67. NK Tanaka, T Awasaki, T Shimada and K Ito (2004) Integration of chemosensory pathways in the Drosophila second-order olfactory centers. Curr Biol 14 449-457.
68. F Zhang, F Ronca, RJ Linhardt and RU Margolis (2004) Structural determinants of heparan sulfate interactions with Slit proteins. Biochem Biophys Res Commun 317 352-357.
69. E Hohenester, S Hussain and JA Howitt (2006) Interaction of the guidance molecule Slit with cellular receptors. Biochem Soc Trans 34 418-421.
70. SA Hussain, M Piper, N Fukuhara, L Strochlic, G Cho, JA Howitt, Y Ahmed, AK Powell, JE Turnbull, CE Holt and E Hohenester (2006) A molecular mechanism for the heparan sulfate dependence of Slit-Robo signaling. J Biol Chem 281 39693-39698.
71. AD Cooper (1997) Hepatic uptake of chylomicron remnants. J Lipid Res 38 2173-2192.
72. RW Mahley and ZS Ji (1999) Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 40 1-16.
73. DK Swertfeger and DY Hui (2001) Apolipoprotein E: a cholesterol transport protein with lipid transport-independent cell signaling properties. Front Biosci 6 D526-D535.
74. DK Swertfeger and DY Hui (2001) Apolipoprotein E receptor binding versus heparan sulfate proteoglycan binding in its regulation of smooth muscle cell migration and proliferation. J Biol Chem 276 25043-25048.
75. HG Bazin, MA Marques, AP Owens 3rd, RJ Linhardt and KA Crutcher (2002) Inhibition of apolipoprotein E-related neurotoxicity by glycosaminoglycans and their oligosaccharides. Biochemistry 41 8203-8211.
76. ZS Ji, RE Pitas and RW Mahley (1998) Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. Apolipoproteins E3 and E2 greater than e4. J Biol Chem 273 13452-13460.
77. RW Mahley and SC Rall Jr (2000) Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1 507-537.
78. LP Aggerbeck, JR Wetterau, KH Weisgraber, CS Wu and FT Lindgren (1988) Human apolipoprotein E3 in aqueous solution. II. Properties of the amino- and carboxyl-terminal domains. J Biol Chem 263 6249-6258.
79. C Wilson, MR Wardell, KH Weisgraber, RW Mahley and DA Agard (1991) Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252 1817-1822.
80. M Zaiou, KS Arnold, YM Newhouse, TL Innerarity, KH Weisgraber, ML Segall, MC Phillips and S Lund-Katz (2000) Apolipoprotein E; -low density lipoprotein receptor interaction. Influences of basic residue and amphipathic alpha-helix organization in the ligand. J Lipid Res 41 1087-1095.
81. JP Segrest, DW Garber, CG Brouillette, SC Harvey and GM Anantharamaiah (1994) The amphipathic alpha helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem 45 303-369.
82. JA Westerlund and KH Weisgraber (1993) Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization. J Biol Chem 268 15745-15750.
83. AD Cardin, N Hirose, DT Blankenship, RL Jackson, JA Harmony, DA Sparrow and JT Sparrow (1986) Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. Biochem Biophys Res Commun 134 783-789.
84. KH Weisgraber, SC Rall Jr, RW Mahley, RW Milne, YL Marcel and JT Sparrow (1986) Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J Biol Chem 261 2068-2076.
85. J Dong, CA Peters-Libeu, KH Weisgraber, BW Segelke, B Rupp, I Capila, MJ Hernaiz, LA LeBrun and RJ Linhardt (2001) Interaction of the N-terminal domain of apolipoprotein E4 with heparin. Biochemistry 40 2826-2834.
86. CP Libeu, S Lund-Katz, MC Phillips, S Wehrli, MJ Hernaiz, I Capila, RJ Linhardt, RL Raffai, YM Newhouse, F Zhou and KH Weisgraber (2001) New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E. J Biol Chem 276 39138-39144.
87. H Saito, P Dhanasekaran, D Nguyen, F Baldwin, KH Weisgraber, S Wehrli, MC Phillips and S Lund-Katz (2003) Characterization of the heparin binding sites in human apolipoprotein E. J Biol Chem 278 14782-14787.
88. M Futamura, P Dhanasekaran, T Handa, MC Phillips, S Lund-Katz and H Saito (2005) Two-step mechanism of binding of apolipoprotein E to heparin: implications for the kinetics of apolipoprotein E-heparan sulfate proteoglycan complex formation on cell surfaces. J Biol Chem 280 5414-5422.
89. U Olsson, G Ostergren-Lunden and J Moses (2001) Glycosaminoglycan-lipoprotein interaction. Glycoconj J 18 789-797.
90. MS Bosner, T Gulick, DJ Riley, CA Spilburg and LG Lange 3rd (1988) Receptor-like function of heparin in the binding and uptake of neutral lipids. Proc Natl Acad Sci USA 85 7438-7442.
91. HC de Boer, PG de Groot, BN Bouma and KT Preissner (1993) Ternary vitronectin-thrombin-antithrombin III complexes in human plasma. Detection and mode of association. J Biol Chem 268 1279-1283.
92. CR Ill and E Ruoslahti (1985) Association of thrombin-antithrombin III complex with vitronectin in serum. J Biol Chem 260 15610-15615.
93. ER Podack, B Dahlback and JH Griffin (1986) Interaction of S-protein of complement with thrombin and antithrombin III during coagulation. Protection of thrombin by S-protein from antithrombin III inactivation. J Biol Chem 261 7387-7392.
94. KT Preissner and G Muller-Berghaus (1987) Neutralization and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin-binding domain of S protein/vitronectin. J Biol Chem 262 12247-12253.
95. MJ Wells and MA Blajchman (1998) In vivo clearance of ternary complexes of vitronectin-thrombin-antithrombin is mediated by hepatic heparan sulfate proteoglycans. J Biol Chem 273 23440-23447.
96. P Fugedi (2003) The potential of the molecular diversity of heparin and heparan sulfate for drug development. Mini Rev Med Chem 3 659-667.
97. KA Bauer (2003) New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. Chest 124 364S-370S.
98. T Islam, M Butler, SA Sikkander, T Toida and RJ Linhardt (2002) Further evidence that periodate cleavage of heparin occurs primarily through the antithrombin binding site. Carbohydr Res 337 2239-2243.
99. HG Garg, CA Hales, L Yu, M Butler, T Islam, J Xie and RJ Linhardt (2006) Increase in the growth inhibition of bovine pulmonary artery smooth muscle cells by an O-hexanoyl low-molecular-weight heparin derivative. Carbohydr Res 341 2607-2612.
100. CP Page (1991) One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonists. Lancet 337 717-720.
101. SD Bowler, SM Smith and PS Lavercombe (1993) Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis 147 160-163.
102. WJ O'Donnell, M Rosenberg, RW Niven, JM Drazen and E Israel (1992) Acetazolamide and furosemide attenuate asthma induced by hyperventilation of cold, dry air. Am Rev Respir Dis 146 1518-1523.
103. T Ahmed, J Garrigo and I Danta (1993) Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. N Engl J Med 329 90-95.
104. A Gaffney and P Gaffney (1996) Rheumatoid arthritis and heparin. Br J Rheumatol 35 808-809.
105. M Petitou, P Duchaussoy, I Lederman, J Choay, P Sinay, JC Jacquinet and G Torri (1986) Synthesis of heparin fragments. A chemical synthesis of the pentasaccharide O-(2-deoxy-2-sulfamido-6-O-sulfo-alpha-d-glucopyranosyl)-(1–4)-O-(beta-D-glucopyranosyluronic acid)-(1–4)-O-(2-deoxy-2-sulfamido-3,6-di-O-sulfo-alpha-D-glu copyranosyl)-(1–4)-O-(2-O-sulfo-alpha-L-idopyranosyluronic acid)-(1–4)-2-deoxy-2-sulfamido-6-O-sulfo-D-glucopyranose decasodium salt, a heparin fragment having high affinity for antithrombin III. Carbohydr Res 147 221-236.
106. B Kuberan, DL Beeler, M Lech, ZL Wu and RD Rosenberg (2003) Chemoenzymatic synthesis of classical and non-classical anticoagulant heparan sulfate polysaccharides. J Biol Chem 278 52613-52621.
107. J Chen, FY Avci, EM Munoz, LM McDowell, M Chen, LC Pedersen, L Zhang, RJ Linhardt and J Liu (2005) Enzymatic redesigning of biologically active heparan sulfate. J Biol Chem 280 42817-42825.